Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights

Key Phase III Readouts Soon

 
• By Andrew McConaghie

Eli Lilly’s Mounjaro looks set to gain US approval for obesity this year and upcoming Phase III data could help it eclipse the huge success of Novo Nordisk’s Wegovy.

Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly's drug outperformed Novo's in a head-to-head in diabetes, but is now aiming for superiority in obesity treatment as well. • Source: Michael Vi / Shutterstock.com

More from Business

More from Scrip